In patients with interstitial lung disease, rituximab plus mycophenolate mofetil (MMF) is associated with benefits in lung function and progression-free survival compared with MMF plus placebo after 24 weeks of treatment. The safety profile of rituximab plus MMF was similar to that of MMF plus placebo. Read the article in full at erj.ersjournals.com
No comments:
Post a Comment